CKD

TRICIDA INVESTIGATION CONTINUED By Former Louisiana Attorney General: Kahn Swick & Foti, LLC Continues to Investigate the Officers and Directors of Tricida, Inc. - TCDA

Retrieved on: 
Saturday, September 24, 2022

Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA).

Key Points: 
  • Former Attorney General of Louisiana, Charles C. Foti, Jr., Esq., a partner at the law firm of Kahn Swick & Foti, LLC (KSF), announces that KSF continues its investigation into Tricida, Inc. (NasdaqGS: TCDA).
  • Finally, on February 25, 2021, the Company disclosed that the FDA had denied the appeal of its NDA denial.
  • KSFs investigation is focusing on whether Tricidas officers and/or directors breached their fiduciary duties to its shareholders or otherwise violated state or federal laws.
  • About Kahn Swick & Foti, LLC
    KSF, whose partners include former Louisiana Attorney General Charles C. Foti, Jr., is one of the nations premier boutique securities litigation law firms.

EQS-News: How One Company Plans To Help Battle A Silent Killer Globally Through Its New Kidney Disease Medication

Retrieved on: 
Friday, September 23, 2022

Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.

Key Points: 
  • Most people are surprised to learn that chronic kidney disease (CKD) is the fastest growing, non-communicable disease in the United States.
  • In fact, each year, more people die from this silent killer than from breast or prostate cancer.
  • Hyperphosphatemia (elevated phosphorus levels in the blood) is a common complication of CKD affecting over 80% of dialysis patients.
  • UNI-494 is a patent-protected new chemical entity in late preclinical development for the treatment of acute kidney injury.

ProKidney to Present at the Jefferies Cell and Genetic Medicine Summit

Retrieved on: 
Friday, September 23, 2022

WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m.

Key Points: 
  • WINSTON-SALEM, N.C., Sept. 23, 2022 (GLOBE NEWSWIRE) -- ProKidney Corp. (Nasdaq: PROK) (ProKidney), a leading late clinical-stage cellular therapeutics company focused on chronic kidney disease (CKD), today announced that Dr. Tim Bertram, Chief Executive Officer of ProKidney, will present a corporate overview at the Jefferies Cell and Genetic Medicine Summit at 1:30 p.m.
  • Investors attending the conference and interested in meeting with ProKidney management may request a meeting by contacting their Jefferies representative.
  • ProKidney, a pioneer in the treatment of CKD through innovations in cellular therapy, was founded in 2015 after a decade of research.
  • REACT has received Regenerative Medicine Advanced Therapy (RMAT) designation, as well as FDA and EMA guidance, supporting its ongoing Phase 3 clinical program, which launched in January 2022.

HHS Technology Group Partners with Amendola for Strategic PR and Marketing Services

Retrieved on: 
Wednesday, September 21, 2022

SCOTTSDALE, Ariz., Sept. 21, 2022 /PRNewswire/ -- Amendola, a nationally recognized, award-winning healthcare and technology public relations and marketing firm, announced that HHS Technology Group (HTG), a leader in purpose-built data and analytics software and solutions for the public and private sector, has selected the firm as its agency of record to assist with messaging, marketing, and promotion of its distinct technology solutions, including its recent collaboration on the COVID-19 Research Database designed to create a scalable, repeatable model accelerating real-world pandemic research.

Key Points: 
  • "We are excited to deepen our relationship with Amendola as we help answer some of healthcare's most complex questions.
  • Amendola is implementing a comprehensive media and communications plan for HTG to showcase the company's current technology and services, new offerings, accomplishments, customer wins, and industry partnerships.
  • HHS Technology Group is a software and solutions company serving the needs of commercial enterprises and government agencies.
  • HHS Technology Group delivers modular software solutions, custom development, and integration services for the modernization and operation of systems supporting a broad spectrum of business and government needs.

Global Blood Dialyzer Market Report 2022: Increased Prevalence of Kidney Disease Fueling Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

Blood dialyzer, also known as hemodialyzer or artificial kidney, is a device used to filter blood of a person who is suffering from kidney damage.

Key Points: 
  • Blood dialyzer, also known as hemodialyzer or artificial kidney, is a device used to filter blood of a person who is suffering from kidney damage.
  • Hemodialyzer accomplishes extracorporeal removal of waste products such as creatinine, urea, and free water from the blood in states of kidney failure.
  • Rising geriatric population and increased prevalence of chronic kidney diseases will lead to increasing demand for blood dialyzers in the global market.
  • Insights from this report would allow marketers and the management authorities of the companies to make informed decision regarding their future product launches, technology up-gradation, market expansion, and marketing tactics
    The global blood dialyzer market report caters to various stakeholders in this industry including investors, suppliers, product manufacturers, distributors, new entrants, and financial analysts
    Global Blood Dialyzer Market , By Product Type:
    Global Blood Dialyzer Market , By Dialysis Membrane Material:
    Global Blood Dialyzer Market , By End User:

Global End Stage Renal Disease Market Report (2022 to 2030) - Growing Prevalence of Diabetes and Hypertension is Driving Growth - ResearchAndMarkets.com

Retrieved on: 
Tuesday, September 20, 2022

The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.

Key Points: 
  • The global end stage renal disease market size is anticipated to reach USD 261.64 billion by 2030, registering a CAGR of 12.9% over the forecast period.
  • Chronic Kidney Disease (CKD) is one of the major causes of increasing kidney failure rates among patients.
  • Technological advancements in the treatment of renal failure are another factor expediting the market growth for ESRD.
  • End Stage Renal Disease Market Variables, Trends & Scope

National Kidney Foundation Election Center Relaunches as Campaign Season Kicks Off

Retrieved on: 
Monday, September 19, 2022

NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The National Kidney Foundation (NKF) is working to ensure kidney patients make their voices heard in this November's midterm elections. The NKF Election Center empowers kidney advocates across the country to find information quickly and easily on voting options in their federal elections. The site offers information about the candidates running and provides key dates and deadlines for voting early, absentee, or in-person.

Key Points: 
  • NEW YORK, Sept. 19, 2022 /PRNewswire/ -- The National Kidney Foundation (NKF) is working to ensure kidney patients make their voices heard in this November's midterm elections.
  • The NKF Election Center empowers kidney advocates across the country to find information quickly and easily on voting options in their federal elections.
  • NKF Election Center provides info & guidance for kidney patients on voting safely during the ongoing COVID-19 pandemic!
  • The NKF Election Center also provides information and guidance for kidney patients about voting safely during the ongoing COVID-19 pandemic.

Global Dialysis Market Report 2022: Growing Number of Diabetic and Hypertension Patients Fueling Sector - ResearchAndMarkets.com

Retrieved on: 
Friday, September 16, 2022

The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.

Key Points: 
  • The "Dialysis Market: Global Industry Trends, Share, Size, Growth, Opportunity and Forecast 2022-2027" report has been added to ResearchAndMarkets.com's offering.
  • The global dialysis market reached a value of US$ 104.13 Billion in 2021.
  • The growing number of diabetic and hypertension patients along with the increasing incidences of end-stage renal disease (ESRD) are primarily driving the global dialysis market.
  • Additionally, the introduction of sorbent-based regenerative technology that enables the delivery of high-dose dialysis with a low volume of dialysis solution while removing toxins is expected to drive the global dialysis market in the coming years.

SHAREHOLDER ALERT: Kaskela Law LLC Announces Investigation of Tricida, Inc. (TCDA) and Encourages Long-Term TCDA Stockholders to Contact the Firm

Retrieved on: 
Thursday, September 15, 2022

PHILADELPHIA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Tricida, Inc. (Tricida or the Company) (NASDAQ: TCDA) on behalf of the Companys long-term stockholders.

Key Points: 
  • PHILADELPHIA, Sept. 15, 2022 (GLOBE NEWSWIRE) -- Kaskela Law LLC announces that it is investigating Tricida, Inc. (Tricida or the Company) (NASDAQ: TCDA) on behalf of the Companys long-term stockholders.
  • Veverimer is intended to slow the progression of chronic kidney disease (CKD) through the treatment of metabolic acidosis.
  • Current Tricida stockholders who purchased or acquired shares of the Companys stock prior to August 1, 2019 are encouraged to contact Kaskela Law LLC (D. Seamus Kaskela, Esq.
  • For additional information about Kaskela Law LLC please visit www.kaskelalaw.com .

MC2 Therapeutics announces initiation of a Phase 2 clinical trial in CKD-aP

Retrieved on: 
Wednesday, September 14, 2022

The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.

Key Points: 
  • The active component of MC2-25 Cream is a di-peptide, which is formulated in MC2 Therapeutics' proprietary formulation and drug delivery system PAD Technology.
  • The trial is a Phase 2, randomized, multicenter, double-blind, parallel-group trial in subjects with CKD-aP stages 3-5.
  • Fueled by an entrepreneurial mindset and creativity, MC2 Therapeutics aims to set new standards in treatment satisfaction for people with skin conditions.
  • For additional information on MC2 Therapeutics Group, pleasevisit www.mc2therapeutics.com
    View original content to download multimedia: https://www.prnewswire.com/news-releases/mc2-therapeutics-announces-init...